Last10K.com

Champions Oncology, Inc. (CSBR) SEC Filing 10-K Annual Report for the fiscal year ending Saturday, April 30, 2022

SEC Filings

CSBR Annual Reports

Champions Oncology, Inc.

CIK: 771856 Ticker: CSBR
Exhibit 99.1

fy2016pr_image1a20.jpg                     NEWS

One University Plaza, Suite 307 Hackensack, NJ 07601


Champions Oncology Reports Quarterly Revenue of $12.9 Million
Record Annual Revenue of $49.1 Million

Hackensack, NJ – July 21, 2022 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for the year and fourth fiscal quarter ended April 30, 2022.

Fourth Quarter and Fiscal Year 2022 Financial and Recent Business Highlights:
Fourth quarter revenue increased 22% to $12.9 million
Record annual revenue of $49.1 million, an increase of 20% year-over-year
Achieved high end of revenue guidance of 20%
Gross margin improved to 52% for fiscal year 2022
Adjusted EBITDA of $3.1 million for fiscal year 2022

Ronnie Morris, CEO of Champions, commented, “Fiscal year 2022 was an outstanding year for Champions as we successfully expanded our business lines while continuing to develop and implement our longer term strategies. Our ex-vivo business was especially promising as we saw rising demand for those services. Our computational discovery tools continue to evolve and this upcoming year will focus on moving these programs into preclinical development."

David Miller, CFO of Champions added, “We realized another year of financial milestones, reaching a record $49.1 million in revenue and delivering 20% top line growth, in line with the high end of revenue guidance. Our pipeline of opportunities remains robust and with the expansion of our platforms, we are well positioned to deliver strong financial results in fiscal year 2023. We’re projecting another year of top line revenue growth in the 20% range.”

Fourth Fiscal Quarter Financial Results

Total revenue for the fourth quarter of fiscal 2022 was $12.9 million, an increase of 22%, compared to $10.6 million for the same period last year. The increase in revenue was due to continued demand and larger study sizes for our pharmacology studies, including in-vivo and ex-vivo services. Total costs and operating expenses for the fourth quarter of fiscal 2022 were $13.2 million compared to $11.0 million for the fourth quarter of fiscal 2021, an increase of $2.2 million or 20%.

For the fourth quarter of fiscal 2022, Champions reported a loss from operations of $311,000, which includes $188,000 in stock-based compensation and $568,000 in depreciation and amortization compared to a loss from operations of $456,000, inclusive of $161,000 in stock-based compensation and $302,000 in depreciation and amortization in the fourth quarter of fiscal 2021. Excluding stock-based compensation, depreciation and amortization expenses, Champions


The following information was filed by Champions Oncology, Inc. (CSBR) on Thursday, July 21, 2022 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Champions Oncology, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Champions Oncology, Inc..

Continue

Assess how Champions Oncology, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Champions Oncology, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Revenue
Financial
Other
Filter Subcategory:
All
Product
Cash Flow
Expense
Income
Geography
Other
Inside Champions Oncology, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Audit Information
Cover
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statement Of Changes In Stockholders??? Equity
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations
Accounts Receivable, Unbilled Services And Deferred Revenue
Accounts Receivable, Unbilled Services And Deferred Revenue (Tables)
Accounts Receivable, Unbilled Services And Deferred Revenue - Narrative (Details)
Accounts Receivable, Unbilled Services And Deferred Revenue - Summary Of Accounts Receivable And Unbilled Services (Details)
Accounts Receivable, Unbilled Services And Deferred Revenue - Summary Of Deferred Revenue (Details)
Commitments And Contingencies
Commitments And Contingencies - Narrative (Details)
Earnings Per Share
Earnings Per Share (Tables)
Earnings Per Share - Calculations Of Earnings Per Share (Details)
Earnings Per Share - Summary Of Potentially Dilutive Stock-Based Instruments (Details)
Leases
Leases (Details)
Leases (Tables)
Leases - Future Minimum Lease Payments (Details)
Leases - Rou Assets And Lease Liabilities (Details)
Organization And Basis Of Presentation
Organization And Basis Of Presentation - Narrative (Details)
Property And Equipment
Property And Equipment (Tables)
Property And Equipment - Narrative (Details)
Property And Equipment - Summary Of Property And Equipment (Details)
Provision For Income Taxes
Provision For Income Taxes (Tables)
Provision For Income Taxes - Change In Uncertain Tax Positions (Details)
Provision For Income Taxes - Components Of Deferred Tax Assets And Liabilities (Details)
Provision For Income Taxes - Components Of Provision (Benefit) For Income Taxes (Details)
Provision For Income Taxes - Narrative (Details)
Provision For Income Taxes - Reconciliation Of Effective Tax Rate (Details)
Related Party Transactions
Related Party Transactions - Narrative (Details)
Revenue From Contracts With Customers
Revenue From Contracts With Customers (Details)
Revenue From Contracts With Customers (Tables)
Significant Customers
Significant Customers (Details)
Stock-Based Payments
Stock-Based Payments (Tables)
Stock-Based Payments - Allocation Of Stock-Based Compensation Costs (Details)
Stock-Based Payments - Narrative (Details)
Stock-Based Payments - Stock Option Activity (Details)
Stock-Based Payments - Stock Option Grants Assumptions (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies - Narrative (Details)
Summary Of Significant Accounting Policies - Revenue Recognition (Details)
Ticker: CSBR
CIK: 771856
Form Type: 10-K Annual Report
Accession Number: 0001628280-22-019309
Submitted to the SEC: Fri Jul 22 2022 4:28:05 PM EST
Accepted by the SEC: Fri Jul 22 2022
Period: Saturday, April 30, 2022
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/csbr/0001628280-22-019309.htm